Abstract
VEGFR inhibitors are in broad use for the treatment of metastatic renal-cell carcinoma, gastrointestinal stromal tumors and hepatocellular carcinoma and in development in a number of other oncology indications, including colorectal cancer, non-small-cell lung cancer, pancreatic cancer, thyroid malignancies, ovarian cancer, breast cancer and sarcomas. This Review outlines the structure–activity relationships of the 44 VEGFR inhibitors currently in development. An overview of the pharmacokinetic profile of each molecule and its stage in development is provided. Phase III clinical trials being conducted for licensing of these agents for specific indications and phase III developmental efficacy trials are described in detailed tables that include the disease studied, trial design including combination therapy, study end points, and projected or final accrual. The relative frequency of on-target and off-target adverse events observed in 3,060 patients is described for a subset of agents in development in clinical trials sponsored by the National Cancer Institute. No interagent comparisons were undertaken and no data from pharmaceutical pharmacovigilance databases were used. The on-target effects seem to be mechanistically based and predicted by VEGFR inhibition. Small-molecule inhibitors of angiogenesis are active in a wide variety of malignancies and fill a unique niche for cancer therapeutics.
Key Points
-
Small-molecule inhibitors of VEGFRs are in clinical development both as single agents and in combination with other cancer therapies; these agents are licensed for use in a limited number of indications
-
Small-molecule inhibitors of VEGFRs are often designed to inhibit other receptors as well, so these agents have a varied adverse-event profile and spectrum of activity
-
Sunitinib and sorafenib are indicated for the treatment of renal-cell carcinoma; sunitinib is also used to treat gastrointestinal stromal cell tumors and sorafenib is also used to treat hepatocellular carcinoma
-
Toxic effects of VEGFR inhibitors include hypertension, proteinuria, hemorrhage and/or bleeding, hypothyroidism, fistula, bowel perforation, left ventricular diastolic dysfunction, thrombotic microangiopathy, reversible posterior leukoencephalopathy syndrome and arterial thrombosis
-
The off-target toxic effects of VEGFR inhibitors are attributed to their split kinase activity (which can be on-target for a specific kinase inhibitor), comorbid illness or complication caused by the cancer
-
The identification of biomarkers to personalize treatment with angiogenesis inhibitors, such as VEGFR inhibitors, is a pressing medical need
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Dvorak, H. F. Angiogenesis: update 2005. J. Thromb. Haemost. 3, 1835–1842 (2005).
Ferrara, N. & Kerbel, R. S. Angiogenesis as a therapeutic target. Nature 438, 967–974 (2005).
Carmeliet, P. VEGF as a key mediator of angiogenesis in cancer. Oncology 69 (Suppl. 3), 4–10 (2005).
Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182–1186 (1971).
Verheul, H. M., Voest, E. E. & Schlingemann, R. O. Are tumours angiogenesis-dependent? J. Pathol. 202, 5–13 (2004).
Zhong, H. & Bowen, J. P. Antiangiogenesis drug design: multiple pathways targeting tumor vasculature. Curr. Med. Chem. 13, 849–862 (2006).
Keck, P. J. et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 246, 1309–1312 (1989).
Senger, D. R., Connolly, D. T., Van de Water, L., Feder, J. & Dvorak, H. F. Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res. 50, 1774–1778 (1990).
Roy, H., Bhardwaj, S. & Yla-Herttuala, S. Biology of vascular endothelial growth factors. FEBS Lett. 580, 2879–2887 (2006).
Ferrara, N. & Henzel, W. J. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun. 161, 851–858 (1989).
Carmeliet, P. Angiogenesis in life, disease and medicine. Nature 438, 932–936 (2005).
Ferrara, N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 9 (Suppl. 1), 2–10 (2004).
Holmes, D. I. & Zachary, I. The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease. Genome Biol. 6, 209 (2005).
Levy, A. P., Levy, N. S. & Goldberg, M. A. Post-transcriptional regulation of vascular endothelial growth factor by hypoxia. J. Biol. Chem. 271, 2746–2753 (1996).
Levy, A. P., Levy, N. S., Wegner, S. & Goldberg, M. A. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J. Biol. Chem. 270, 13333–13340 (1995).
Mukhopadhyay, D., Tsiokas, L. & Sukhatme, V. P. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res. 55, 6161–6165 (1995).
Maher, E. R. & Kaelin, W. G., Jr . von Hippel–Lindau disease. Medicine (Baltimore) 76, 381–391 (1997).
Jiang, B. H., Agani, F., Passaniti, A. & Semenza, G. L. v-Src induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res. 57, 5328–5335 (1997).
Klagsbrun, M. & D'Amore, P. A. Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev. 7, 259–270 (1996).
Shibuya, M. Structure and dual function of vascular endothelial growth factor receptor-1 (Flt-1). Int. J. Biochem. Cell Biol. 33, 409–420 (2001).
Wiesmann, C., Muller, Y. A. & de Vos, A. M. Ligand-binding sites in Ig-like domains of receptor tyrosine kinases. J. Mol. Med. 78, 247–260 (2000).
Schlessinger, J. & Ullrich, A. Growth factor signaling by receptor tyrosine kinases. Neuron 9, 383–391 (1992).
Dvorak, H. F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. 20, 4368–4380 (2002).
Karkkainen, M. J. & Petrova, T. V. Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis. Oncogene 19, 5598–5605 (2000).
Nagy, J. A. et al. Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. J. Exp. Med. 196, 1497–1506 (2002).
Ullrich, A. & Schlessinger, J. Signal transduction by receptors with tyrosine kinase activity. Cell 61, 203–212 (1990).
Arora, A. & Scholar, E. M. Role of tyrosine kinase inhibitors in cancer therapy. J. Pharmacol. Exp. Ther. 315, 971–979 (2005).
Hubbard, S. R. Structural analysis of receptor tyrosine kinases. Prog. Biophys. Mol. Biol. 71, 343–358 (1999).
Sonpavde, G. & Hutson, T. E. Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Curr. Oncol. Rep. 9, 115–119 (2007).
Paavonen, K., Puolakkainen, P., Jussila, L., Jahkola, T. & Alitalo, K. Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing. Am. J. Pathol. 156, 1499–1504 (2000).
Olsson, A. K., Dimberg, A., Kreuger, J. & Claesson-Welsh, L. VEGF receptor signalling in control of vascular function. Nat. Rev. Mol. Cell Biol. 7, 359–371 (2006).
Matsumoto, T. & Claesson-Welsh, L. VEGF receptor signal transduction. Science STKE 2001, RE21 (2001).
Takahashi, T., Yamaguchi, S., Chida, K. & Shibuya, M. A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-γ and DNA synthesis in vascular endothelial cells. EMBO J. 20, 2768–2778 (2001).
Dayanir, V., Meyer, R. D., Lashkari, K. & Rahimi, N. Identification of tyrosine residues in vascular endothelial growth factor receptor-2/FLK-1 involved in activation of phosphatidylinositol 3-kinase and cell proliferation. J. Biol. Chem. 276, 17686–17692 (2001).
Fujio, Y. & Walsh, K. Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner. J. Biol. Chem. 274, 16349–16354 (1999).
Sakai, R. et al. The mammalian ShcB and ShcC phosphotyrosine docking proteins function in the maturation of sensory and sympathetic neurons. Neuron 28, 819–833 (2000).
Warner, A. J., Lopez-Dee, J., Knight, E. L., Feramisco, J. R. & Prigent, S. A. The Shc-related adaptor protein, Sck, forms a complex with the vascular-endothelial-growth-factor receptor KDR in transfected cells. Biochem. J. 347, 501–509 (2000).
Shu, X., Wu, W., Mosteller, R. D. & Broek, D. Sphingosine kinase mediates vascular endothelial growth factor-induced activation of Ras and mitogen-activated protein kinases. Mol. Cell Biol. 22, 7758–7768 (2002).
Meadows, K. N., Bryant, P. & Pumiglia, K. Vascular endothelial growth factor induction of the angiogenic phenotype requires Ras activation. J. Biol. Chem. 276, 49289–49298 (2001).
Takahashi, T., Ueno, H. & Shibuya, M. VEGF activates protein kinase C-dependent, but Ras-independent Raf–MEK–MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene 18, 2221–2230 (1999).
Abedi, H. & Zachary, I. Vascular endothelial growth factor stimulates tyrosine phosphorylation and recruitment to new focal adhesions of focal adhesion kinase and paxillin in endothelial cells. J. Biol. Chem. 272, 15442–15451 (1997).
Le Boeuf, F., Houle, F. & Huot, J. Regulation of vascular endothelial growth factor receptor 2-mediated phosphorylation of focal adhesion kinase by heat shock protein 90 and Src kinase activities. J. Biol. Chem. 279, 39175–39185 (2004).
Fong, G. H., Rossant, J., Gertsenstein, M. & Breitman, M. L. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376, 66–70 (1995).
Makinen, T. et al. Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J. 20, 4762–4773 (2001).
Karkkainen, M. J. et al. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat. Immunol. 5, 74–80 (2004).
Wang, J. F., Zhang, X. & Groopman, J. E. Activation of vascular endothelial growth factor receptor-3 and its downstream signaling promote cell survival under oxidative stress. J. Biol. Chem. 279, 27088–27097 (2004).
Korpelainen, E. I., Karkkainen, M., Gunji, Y., Vikkula, M. & Alitalo, K. Endothelial receptor tyrosine kinases activate the STAT signaling pathway: mutant Tie-2 causing venous malformations signals a distinct STAT activation response. Oncogene 18, 1–8 (1999).
Blume-Jensen, P. & Hunter, T. Oncogenic kinase signalling. Nature 411, 355–365 (2001).
Hubbard, S. R. & Till, J. H. Protein tyrosine kinase structure and function. Annu. Rev. Biochem. 69, 373–398 (2000).
Manning, G., Whyte, D. B., Martinez, R., Hunter, T. & Sudarsanam, S. The protein kinase complement of the human genome. Science 298, 1912–1934 (2002).
Woolfrey, J. R. & Weston, G. S. The use of computational methods in the discovery and design of kinase inhibitors. Curr. Pharm. Des. 8, 1527–1545 (2002).
Cohen, P. The development and therapeutic potential of protein kinase inhibitors. Curr. Opin. Chem. Biol. 3, 459–465 (1999).
Relf, M. et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor β1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res. 57, 963–969 (1997).
Taylor, A. P. et al. Tumor-specific regulation of angiogenic growth factors and their receptors during recovery from cytotoxic therapy. Clin. Cancer Res. 8, 1213–1222 (2002).
Kiselyov, A., Balakin, K. V. & Tkachenko, S. E. VEGF/VEGFR signalling as a target for inhibiting angiogenesis. Expert Opin. Investig. Drugs 16, 83–107 (2007).
Underiner, T. L., Ruggeri, B. & Gingrich, D. E. Development of vascular endothelial growth factor receptor (VEGFR) kinase inhibitors as anti-angiogenic agents in cancer therapy. Curr. Med. Chem. 11, 731–745 (2004).
Boyer, S. J. Small molecule inhibitors of KDR (VEGFR-2) kinase: an overview of structure activity relationships. Curr. Top. Med. Chem. 2, 973–1000 (2002).
Hennequin, L., Ple, P., Stokes, E. & McKerrecher, D. Quinozoline derivatives as angiogenesis inhibitors. WO0047212 (2000).
Ellis, L. M. & Hicklin, D. J. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat. Rev. Cancer 8, 579–591 (2008).
Clifford, S. C. & Maher, E. R. Von Hippel–Lindau disease: clinical and molecular perspectives. Adv. Cancer Res. 82, 85–105 (2001).
Ouyang, B. et al. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo. Clin. Cancer Res. 12, 1785–1793 (2006).
Manley, P. W. et al. Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J. Med. Chem. 45, 5687–5693 (2002).
Traxler, P. et al. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res. 64, 4931–4941 (2004).
Ghosh, S. et al. Alpha-cyano-beta-hydroxy-beta-methyl-N-[4-(trifluoromethoxy)phenyl] propenamide: an inhibitor of the epidermal growth factor receptor tyrosine kinase with potent cytotoxic activity against breast cancer cells. Clin. Cancer Res. 4, 2657–2668 (1998).
Klohs, W. D., Fry, D. W. & Kraker, A. J. Inhibitors of tyrosine kinase. Curr. Opin. Oncol. 9, 562–568 (1997).
Lawrence, D. S. & Niu, J. Protein kinase inhibitors: the tyrosine-specific protein kinases. Pharmacol. Ther. 77, 81–114 (1998).
Polverino, A. et al. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res. 66, 8715–8721 (2006).
Wedge, S. R. et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 65, 4389–4400 (2005).
Hennequin, L. F. et al. Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. J. Med. Chem. 45, 1300–1312 (2002).
Wedge, S. R. et al. ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy. Cancer Res. 60, 970–975 (2000).
Wedge, S. R. et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 62, 4645–4655 (2002).
Wilhelm, S. M. et al. BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF–MEK–ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64, 7099–7109 (2004).
Jain, R. K. et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat. Rev. Clin. Oncol. 6, 327–338 (2009).
Steeghs, N. et al. Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor. Clin. Cancer Res. 14, 3470–3476 (2008).
Mross, K. et al. Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib. Eur. J. Cancer 43, 55–63 (2007).
Moreno-Aspitia, A. et al. Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336. J. Clin. Oncol. 27, 11–15 (2009).
Burstein, H. J. et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J. Clin. Oncol. 26, 1810–1816 (2008).
Hilberg, F. et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 68, 4774–4782 (2008).
Marathe, P. H. Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate. Cancer Chemother. Pharmacol. doi:10.1007/s00280-009-1002-0
Eremina, V. et al. VEGF inhibition and renal thrombotic microangiopathy. N. Engl. J. Med. 358, 1129–1136 (2008).
Strumberg, D. et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 12, 426–437 (2007).
Strumberg, D. et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43–9006 in patients with advanced refractory solid tumors. J. Clin. Oncol. 23, 965–972
Rugo, H. S. et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J. Clin. Oncol. 23, 5474–5483 (2005).
Rosen, L. S. et al. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 25, 2369–2376 (2007).
Drevs, J. et al. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 25, 3045–3054 (2007).
Ryan, C. J. et al. Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC). Invest. New Drugs 25, 445–451 (2007).
Holden, S. N. et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann. Oncol. 16, 1391–1397 (2005).
Strumberg, D. et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 12, 426–437 (2007).
Strumberg, D. et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43–9006 in patients with advanced refractory solid tumors. J. Clin. Oncol. 23, 965–972 (2005).
Strumberg, D. et al. Phase I dose escalation study of telatinib (BAY 57–9352) in patients with advanced solid tumours. Br. J. Cancer 99, 1579–1585 (2008).
Sarker, D. et al. A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors. Clin. Cancer Res. 14, 2075–2081 (2008).
Cohen, R. B. et al. A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547, 632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC). Cancer Chemother. Pharmacol. 60, 81–89 (2007).
Mross, K. et al. Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours. Eur. J. Cancer 41, 1291–1299 (2005).
Kuenen, B. C. et al. Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J. Clin. Oncol. 20, 1657–1667 (2002).
Salzberg, M. et al. A phase I study with oral SU5416 in patients with advanced solid tumors: a drug inducing its clearance. Invest. New Drugs 24, 299–304 (2006).
Sessa, C. et al. Phase I clinical and pharmacological evaluation of the multi-tyrosine kinase inhibitor SU006668 by chronic oral dosing. Eur. J. Cancer 42, 171–178 (2006).
Xiong, H. Q. et al. A phase I surrogate endpoint study of SU6668 in patients with solid tumors. Invest. New Drugs 22, 459–466 (2004).
Faivre, S. et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J. Clin. Oncol. 24, 25–35 (2006).
Garton, A. J. et al. OSI-930: a novel selective inhibitor of Kit and kinase insert domain receptor tyrosine kinases with antitumor activity in mouse xenograft models. Cancer Res. 66, 1015–1024 (2006).
Author information
Authors and Affiliations
Corresponding author
Supplementary information
Rights and permissions
About this article
Cite this article
Ivy, S., Wick, J. & Kaufman, B. An overview of small-molecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol 6, 569–579 (2009). https://doi.org/10.1038/nrclinonc.2009.130
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2009.130